Veradermics, Incorporated (MANE) Income Statement
MANE 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsMANE revenue and net income
MANE growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
MANE quarterly EPS vs estimates
Veradermics beat the analyst EPS estimate in 2 of the last 3 quarters. Next report: November 10, 2026 (estimate $-0.59).
MANE income statement
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Research & development | $62.1M | $23.3M | $15.0M |
| Sales, general & admin | $10.3M | $3.5M | $2.4M |
| Total operating expenses | $72.3M | $26.8M | $17.3M |
| Operating income | −$72.3M | −$26.8M | −$17.3M |
| Interest income | $1.6M | $481,000 | $870,000 |
| Interest expense | $0 | $585,000 | $36,000 |
| Income before taxes | −$70.0M | −$26.5M | −$16.5M |
| Net income | −$70.0M | −$26.5M | −$16.5M |
| EBITDA | −$70.0M | −$25.9M | −$16.5M |
| EPS (diluted) | −$104.54 | −$0.13 | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Research & development | $18.6M | $20.9M | $18.2M | $18.1M | $14.3M | $11.4M | $5.0M |
| Sales, general & admin | $10.9M | $8.9M | $4.8M | $2.3M | $1.7M | $1.5M | $1.0M |
| Total operating expenses | $29.6M | $29.9M | $23.0M | $20.3M | $16.1M | $12.9M | $6.0M |
| Operating income | −$29.6M | −$29.9M | −$23.0M | −$20.3M | −$16.1M | −$12.9M | −$6.0M |
| Interest income | $4.8M | $2.5M | $906,000 | $71,000 | $103,000 | $482,000 | $209,000 |
| Interest expense | — | — | $532,000 | — | — | — | $292,000 |
| Income before taxes | −$23.5M | −$27.2M | −$21.8M | −$20.1M | −$15.6M | −$12.4M | −$5.7M |
| Net income | −$23.5M | −$27.2M | −$21.8M | −$20.1M | −$15.6M | −$12.4M | −$5.7M |
| EBITDA | −$29.6M | −$27.2M | −$21.3M | −$19.2M | −$16.1M | — | −$5.4M |
| EPS (diluted) | −$0.58 | −$0.73 | −$104.54 | — | — | — | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in MANE's financial statements (latest annual report filed December 31, 2025); data from EODHD. Sales, general & administrative expenses include sales and marketing.
MANE financial results
Veradermics reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $70.0 million. Diluted earnings per share came to −$104.54.
See the MANE stock overview for the latest quote and news, or the MANE chart for price history and technical indicators.
MANE income statement FAQ
Does Veradermics have revenue?
Veradermics reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Veradermics profitable?
No. Veradermics reported a net loss of $70.0 million in fiscal 2025.
How much does Veradermics spend on research and development?
Veradermics spent $62.1 million on research and development in fiscal 2025.
What are Veradermics's earnings per share?
Veradermics earned $-104.54 per diluted share in fiscal 2025, compared with $-0.13 a year earlier.
When will Veradermics report its next earnings?
Veradermics is expected to report results for the quarter ending September 30, 2026 on November 10, 2026.
When does Veradermics's fiscal year end?
Veradermics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on December 31, 2025.